NanoRegMed creates new nanomaterials to bring your innovations to the future
Based in the London BioScience Innovation Centre, NanoRegMed creates and brings to market innovative materials and components for materials for a wide variety of applications.We are commercialising a new family of biodegradable and non-biodegradable graphene-based nanocomposites, Hastalex® and BioHastalex® that help repair or replace damaged or missing organs and are superior to any other material available today. We also licence our materials and collaborate with other companies for non-medical applications.
We produce reduced graphene oxide and functionalised graphene oxide with superior levels of functionalisation certified by the UK National Physical Laboratory
Our unique materials Hastalex® and BioHastalex® can be tailored for various applications with properties like extreme strength, conductivity, elasticity and hydrophobicity
NanoRegMed can act as an R&D partner on projects and grant applications globally and in a variety of fields.
Goodfellow and NanoRegMed have announced a partnership facilitating the supply by Goodfellow of NanoRegMed's materials. Click here to learn more.
Amelia Seifalian has won an Innovate UK Young Innovator award to use Hastalex to develop developing an artificial material membrane solution to pelvic organ prolapse, which affects 1 in 2 women worldwide.
Corporate Livewire Innovation & Excellence Awards have announced that NanoRegMed is their Biotech company of the year.
Southern Enterprise Awards have awarded NanoRegMed the Most Innovate Biotechnology Company in the UK 2021 award.
With a passion for bettering the lives of everyone through new technology , our innovations are solving some of the most important needs in medicine today.
Alex's career spans decades in the fields of nanotechnology and regenerative medicine. His current projects have led to the development of cardiovascular implants using nanomaterials and stem cell technology, and the development of organs using tissue engineering and nanoparticles for detection and treatment of cancer.
Hana worked in financial services for over 15 years and held senior positions in leading global investment banks. She specialised in commercialising new ideas, opening new markets and creating new products. Her strategies successfully generated significant revenue streams.
Stephen has 30+ years work experience in the industry, including with ICI Pharmaceuticals Ltd, Cardiotech Ltd, Rosehill Polymers Ltd, Pilkington Optronics Ltd and many more.
As is a professor of plastic surgery at Royal Free Hostpial and University College London.
Ash holds an MBBS(Lon)FRCS, FRCS(Plast), PhD(Lon) and MBA(Warwick).
Ameliais a qualified doctor working in the NHS training to be a Gynaecologist. She graduated from UCL medical school where she also completed an integrated BSc inGlobal Health. Amelia is also completing a PhD at Imperial College London developing a novel graphene-based surgical implant using stem cell technology to be used in femalepelvic organ prolapse surgery.
Liberum Health is developing a range of products to address the unmet needs in women's health through different life stages.
-------
